Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients

Published: 28 January 2021| Version 1 | DOI: 10.17632/kyf2cnsxjw.1
Contributors:
Joseph Stoll,
,
,
,
,
,
,

Description

Supplemental Figure 1. Proposed management guidelines for CPX-351-associated purpuric rash. mg, milligrams; kg, kilograms

Files

Institutions

Memorial Sloan Kettering Cancer Center

Categories

Dermatology

Licence